Herpes latency, meningitis, radiculomyelopathy and disseminated infection

Joseph J Sasadeusz, Stephen L Sacks

Introduction
Genital herpes simplex virus (HSV) infection affects a large proportion of the population. A recent seroepidemiologic survey of individuals in the United States of America found that 16-4% of the population were seropositive for herpes simplex virus (HSV) type 2 (HSV-2). Most HSV-2 transmission originates with an asymptomatic partner. Because the majority of affected individuals are asymptomatic and experience periodic virus reactivations, a large reservoir of infectious virus persists.

A fundamental characteristic of all of the herpes viruses is their ability to achieve a state of latency from which they can reactivate. Viral reactivations become clinically evident in a minority of patients. Severity of disease manifestations are dependent upon a variety of virus and host factors. The site of inoculation will usually determine initial disease location(s), if the disease is symptomatic at the time of its primary acquisition. Sites of recurrent disease, on the other hand, are determined by the routing of neural pathways emanating from the site(s) of neuronal latency. For example, HSV type 1 (HSV 1) or HSV-2 may be inoculated initially at any site with subsequent local recurrences also possible in or near that location. Because the majority of human host interactions involve either genital or facial skin or mucous membranes, the majority of HSV disease is manifest on the face and/or genital region. The vast majority of genital herpes is caused by reactivation from latency of HSV-2. Primary genital disease, however, while more commonly caused by transmission of HSV-2, may often be caused by HSV-1, transmission occurring via genital-genital or oral-genital routes, respectively. The converse is true for oral-labial disease which is predominantly HSV-1 and results from face-to-face contact.

Recurrent disease locations are determined by the nature of the individual’s neural recurrence pathway, which, in turn, must also reflect the specific transmission event which identified the initial site of viral inoculation into the new host. Thus, disease manifestations may be highly variable. For example, oral-labial herpes in one person may be transmitted to any target in the new host which directly contacts the mouth. The most common site is the mouth or lips of the viral recipient. However, inoculation to the ophthalmic division of the trigeminal nerve may instead lead to ophthalmic HSV and recurrent keratitis or deeper stromal disease. Inoculation to the finger or hand may be a more likely end-point for an intensivist or a dental hygienist delivering mouth care. Infection of the cribriform plate and the overlying olfactory bulb, may lead to a less common, potentially lethal form of localized HSV infection, herpes encephalitis. Encephalitis passed via this route in adults is caused by HSV-1. HSV-2 encephalitis generally occurs in neonates and results from intrapartum transmission, and less commonly occurs in immunocompromised adults with disseminated infection. Just as the nature of the disease caused by mucocutaneous HSV depends upon the site of infection, HSV may cause a variety of neurological syndromes, ranging from aseptic meningitis to radiculomyelopathy, all of which are defined by the site(s) of involvement. This review will focus on these latter syndromes, specifically addressing what is known of their pathogenesis, manifestations and treatment.

The biology of herpes simplex viruses
HSV is a double stranded DNA virus approximately 150 nm in diameter. It is surrounded by a lipid envelope from which virus-specific glycoproteins protrude, surrounding an icosahedral protein capsid which houses the genome and an amorphous material known as the tegument which, in turn, contains a number of viral-encoded proteins. A number of clinical, epidemiological and biological differences allow distinction between 2 HSV types, HSV-1 and HSV-2. Genital herp can be caused by either HSV-1 or HSV-2. HSV-1 may account for between 7% to 50% of first episode lesions, depending on geographical location, but only causes 2% of recurrent genital herpes. Its genome is linear, approximately 150 kb long. There is a large degree of homology between the genomes of HSV-1 and HSV-2 with about 50% of the sequences being highly conserved. Infection is caused by inoculation of virus onto mucosal surfaces or skin with an epithelial breach. A new replication cycle of HSV commences with attachment of the envelope to cell surface heparan sulphate, fusion with the cell plasma membrane and liberation of nucleocapsids into the cytoplasm. These steps are mediated by membrane virus-derived glycoproteins. The virus then migrates to the nucleus where it is uncoated at nuclear pores and the naked DNA enters the nucleus and circularises. A prepackaged transactivator of transcription, VP16, then initiates the transcription of the first of a cascade of three sets of genes, the immediate early (IE) genes. These gene products then activate the next set of
immune attack and currently available antiviral chemotherapies. As a measure of extent of latent infection, in situ hybridisation studies show that 0.1–3.0% of human neurons contain LATs.15–16 HSV may be subsequently reactivated from its latent state via certain trigger factors, some defined; others not. The virus then travels centrifugally to reinitiate productive infection at a mucocutaneous site. The recurrence is modified by a preexisting immune response, however. In cases where primary disease was clinically evident, recurrences are generally shorter and/or less intense than the primary infection which led originally to the latent state.1 However, where the primary infection was, itself, asymptomatic, reactivations may seem to be of equal or greater clinical intensity.

**The nature of latency**

A hallmark of all herpes viruses is their ability to establish latency. This group of viruses may be subclassified according to the cell type which supports their latent state. Because HSV-1, HSV-2 and varicella zoster virus (VZV) are neurotropic, they are classed as “alpha” herpes viruses.

Several important clinical observations have been made about the latent state. Both human and animal data demonstrate HSV-2 to reactivate much more frequently from sacral latency compared with HSV-1.14 Conversely, HSV-2 reactivates less frequently from a trigeminal latent site.17–18 These observations suggest that viral latency may result from a specific adaptation of a virus type. It is unclear whether these type-specific differences are due to lower frequency rates of the establishment of latency or alternatively, type-dependent differences in rates of reactivation. Reactivation rates do not vary between sexes, however, nor are they dependent upon the relative symptomatic severity of the primary episode.4 Studies of changing reactivation rates with time are contradictory. One suggested a 50% reduction in recurrence rate in men with a history of >4 years as opposed, to those of 6–12 months duration4 while another suggested no difference in rates for individuals infected >5 years as opposed to those infected <5 years.19 Immune competence, however, seems crucial to the maintenance of latency. Patients with defects in cell-mediated immunity, including transplant recipients and patients with the acquired immune deficiency syndrome (AIDS), suffer more frequent and more severe recurrences of HSV.20–23 Animal models show that immune suppression predisposes to in vivo reactivation.24,25 Furthermore, HSV reactivation may be predictably triggered by nonimmunosuppressive stimuli such as trauma to sensory nerves and ultraviolet light,26,27 suggesting that neuronal disturbances are important in the mechanisms of reactivation. Despite recurring neuron-based reactivations, patients with frequent attacks of herpes labialis do not generally suffer neurological deficits in affected dermatomes. This would suggest that reactivations are not associated with destruction of
The role of viral thymidine kinase in latency has been debated. While latent viral infection may be caused by viruses genetically unable to express viral thymidine kinase (TK), reactivation from latency requires TK in a mouse model of HSV-1. Reactivations of TK-deficient HSV-2 without coexistent drug treatment pressure have been observed in some AIDS patients, however, suggesting that reactivations of TK-deficient HSV-2 may be possible. In general, viral heterogeneity is present in reactivatable HSV-2 with TK-deficient phenotypes, such that in vivo complementation of the predominant TK population by a TK subpopulation may be taking place. Acyclovir-resistant reactivations from a patient following clearance of a resistant lesion may thus be either sensitive or resistant to acyclovir.

The establishment and maintenance of latency is a complex process whose outcome is determined by the sum total of the interaction of multiple cellular and viral factors. The nature of these interactions is still incompletely understood. Several lines of evidence suggest that the choice between latency or lytic pathways is determined very early after infection. Ganglionic cells showing no signs of lytic infection but harbouring latent virus are distinct from and appear simultaneously with ganglionic cells undergoing lytic infection, suggesting that initiation of lytic infection is not required for establishment of latency. Further, there is an absence of IE messenger RNAs by in-situ hybridisation in latently-infected cells. In fact, evidence from replication-incompetent mutants suggests that replication is not necessary for establishment of latency. Finally, there is evidence to suggest that restricted gene expression of LATs is an early event and can be detected as early as the fourth day following peripheral inoculation. There is general agreement, however, that there is more than one HSV genome per neuron. It is uncertain whether many virions initially infect the latent cell, whether the DNA is a remnant of early replication prior to establishment of latency or whether the DNA is actually replicated within the neuron following the establishment of latency. IE protein production, particularly α4 protein, is absolutely required for subsequent gene expression and is also responsible for most of the cell damage that eventuates in cell death. Therefore, this is the likely level at which restriction of gene expression occurs.

Upon commencement of lytic infection the gene transcriptional cascade is initiated by the interaction of at least one viral and two host proteins. Transactivation of viral immediate early (IE or α genes) genes is initiated by VP16 which is already present in the tegument. VP 16 mediates this transactivation by forming a complex with at least two cellular factors, one of which is the Oct-1 transcription factor which is critical to enable binding of VP 16 to the octamer-like sequences in the IE gene promoter. Latent viral DNA is probably circular and extrachromosomal, known to be associated with cellular histones and organised into nucleosomes which resemble chromatin, further suggesting that control of viral gene expression during latency is under cellular regulatory factors. The LAT gene may also have a role in maintenance of latency. It is antisense to but overlaps an IE gene, ICP 0, and evidence suggests that it may inhibit the ICP 0 transcript, possibly by formation of an RNA duplex. Contradicting this model is the behaviour of LAT negative mutants which are able to establish and maintain latency but are impaired in induced reactivation.

The factors which cause genes to switch from latent to lytic gene expression are also largely unknown. Triggers of reactivation suggest that latency is a result of a lack of host factors which are critical for the expression of early gene proteins and that external stimuli may activate cellular transcription factors which can induce viral regulatory proteins and begin the lytic cycle. Many stimuli, including ganglionic explantation, have been shown to trigger neuronal transcription factors such as c-fos and c-jun which then alter neuronal gene expression and explanted, latently infected mouse ganglia, demonstrate upregulation of cellular transcription factors, including Oct-1 which precedes viral RNA expression. How these transcription factors may switch genes from latent to lytic expression is unknown. The lytic viral factors of reactivation are the IE transcription factors, the first viral products to appear after explantation. Evidence suggests that ICP 0 may be the crucial viral gene which mediates the switch from latency to lytic cycle. One model proposes that the number of viral DNA copies per cell determines the balance between latency and lytic infection and that perturbations which cause reactivations do so by stimulating DNA replication beyond a critical level where viral gene expression ensues.

**Herpes meningitis**

HSV has been isolated from the CSF of 0-5% to 3% of patients presenting to hospital with aseptic meningitis. In both adults and infants HSV-2 is more commonly isolated than HSV-1. It has been estimated that only a third of patients with HSV-2 meningitis report genital lesions. HSV may also be isolated from the CSF of otherwise normal individuals. HSV meningitis is usually seen in association with primary genital HSV infection where it has been reported to occur at an incidence of 36% in women and 13% of men with primary HSV-2 infections. In most cases symptomatically associated with genital herpes, genital lesions precede meningitis by a mean of approximately one week. The clinical cluster of symptoms includes headache, stiff neck, photophobia, malaise and fever and may be severe enough to require hospitalisation. The CSF typically demonstrates a lymphocytic pleocytosis ranging from 5 to greater than 1000/mm² (median 300-400/mm²) and is usually associated with a glucose greater than 75 mg/dL.
Figure 2  Schematic illustration of the cascade of gene expression involved in the genesis of lytic infection. Also shown are the putative regulatory factors involved directing infection to lytic or latent infection pathways as well as the factors involved in switching from latency to lytic infection.

than 50% of the blood glucose although hypoglycorrhachia has been reported. Further, it is likely that patients with symptomatic primary genital herpes whose extragenital symptoms include fever, and/or headache, and/or mild photophobia may have a low-grade meningitis. HSV-2 meningitis is generally self-limited resolving without long term neurological sequelae. However, transient neurological complaints have actually been reported in the majority of primary genital episode infections associated with meningitis. These included urinary retention, dysaesthesias, paraesthesia, neuralgia, motor weakness, paraparesis, concentration difficulties, periodic headache and impaired hearing. The frequency of recurrent meningitis has been reported at 18.5–30%. The genesis of HSV meningitis is unclear. Rare reports of the isolation of HSV in buffy coats of adults with meningitis together with the observation that HSV CSF isolation only tends to be associated with disseminated infection but not isolated encephalitis suggests a haematogenous route of infection and would also be consistent with the known pathogenesis of other viral meningitides. The association of meningitis with radiculitis and the existence of recurrent meningitis associated with genital recurrences, however, suggests that neurogenic spread may also occur and may partly explain the difficulty of recovery from blood or CSF.

The isolation of HSV during a bout of recurrent aseptic meningitis and three cases of recurrences of Mollaret’s meningitis coincident with the development of genital herpes with subsequent responses to treatment with acyclovir (ACV), suggest HSV as a possible cause of this syndrome, a benign form of recurrent aseptic meningitis. Unfortunately, repeated isolation of HSV from these patients has not been documented and isolation of virus and antigen detection from the CSF of patients with likely HSV-2 recurrent meningitis has been unrewarding. It has been suggested that detection of intrathecal HSV-2 IgG antibody production by immunoblotting in CSF collected three or more days after onset of symptoms may be a useful diagnostic adjunct. There have also been reports of the diagnosis of HSV meningitis using the diagnostic sensitivity of CSF polymerase chain reaction (PCR) and further exploration with this technique may clarify many of the above unsolved issues and offer a diagnostic tool. HSV-2 may be a potential cause of many cases of aseptic meningitis that have previously been undiagnosable without a specific test. HSV PCR of the CSF is likely to demonstrate HSV-2 as the cause for many cases which might have previously been considered idiopathic.

Whether antiviral chemotherapy has any effect on prevention or course of meningeal disease is relatively unknown. Anecdotal reports in primary and recurrent infections suggest response to systemic treatment with acyclovir. This, together with the documented efficacy of acyclovir in primary infections, makes its use for this indication compelling.

Radiculomyelopathy

Radiculomyelopathy presents clinically with numbness, paraesthesias, neuralgic pain of the buttock, perineum or lower limbs, urinary retention, constipation and/or impotence. Symptoms suggest a predominance of autonomic nervous system dysfunction. Physical examination may reveal sacral anaesthesia to fine touch, hyperaesthesia, reduced perineal and bulbocavernous reflexes, reduced rectal sphincter tone and bladder distention. It is usually associated with CSF pleocytosis and elevated protein, may occur with a low glucose in the CSF and may precede and be associated with episodes of clinical aseptic meningitis. Electromyographic studies have shown slowed nerve conduction and fibrillation potentials. In cases of neuropathic bladder, cystometric investigation reveals a flaccid hypotonic curve compatible with a lower motor neuron neuropathic bladder. Symptoms resolve gradually over days to weeks although residual urinary dysfunction, hypeaesthesia, or lower extremity weakness may occasionally persist for months. In heterosexuals it is mainly a complication of primary infection in women but it has been reported to occur in 52% of homosexual men with HSV proctitis which may particularly predispose to this complication. Urinary retention associated with herpes genitals
patients occurs predominantly in females and retention follows lesions on average four days later. Overt signs of HSV infection, however, may be absent; hence HSV infection needs to be considered in the differential diagnosis of all urinary retention in young adults. Normal urinary function usually recovers from three days to three weeks without relapse, although prolonged dysfunction has occurred in the setting of corticosteroid treatment and raises questions as to the wisdom of their use. It is still uncertain whether the pathogenesis involves direct viral inflammation or a post-infectious inflammatory demyelinating process. HSV has also been reported to cause a sciatica syndrome occurring premenstrually in premenopausal women with buttock lesions, which may occur in the absence of lesions and which is responsive to amantidine hydrochloride when given to prevent or abort episodes. A more common presentation of neurogenic pain and/or dysesthesias occurs in the setting of reactivation disease where prodromal manifestations of local discomfort occur at the site of the coming lesion or less commonly, at a remote site within a similar ganglionic distribution. The frequency of such prodromes is approximately 90% and symptoms may occur in the absence of lesions, so called "nonlesional prodromes". Proximal discomfort may last for hours to days and mimics the prodromal discomfort of VZV reactivation. Neuralgia in association with HSV recurrences, although well documented, has been reported rarely although clinical practice suggests it to occur far more frequently, leg and thigh pain being a frequent component of prodromal symptomatology. In contrast to herpes zoster, it is usually unassociated with neurological deficit. Rarely, the typical episodic prodromal pain of recurrent HSV infection becomes chronic and/or unremitting, losing its periodicity and resembling the post-herpetic neuralgia of VZV and may be associated with permanent neurological deficit. Unfortunately, no specific test will currently provide an accurate determination regarding the potential viral aetiology of such symptoms. Probably, the majority of such cases which lack both periodicity with mucocutaneous infection and association with objective neurological deficits, are not caused by HSV at all—even in patients who have proven HSV infection. Alternatively, HSV has been a cause in some individuals, but like post-VZV neuralgia, long-term replication of HSV is not easy to identify even if present. Further, damage done to neurons may be manifested in a post-viral sense, the result of completed viral damage. There is no evidence that long-term or chronic HSV-related pain will respond to acyclovir intervention in the absence of genital sores. Indeed, one study of chronic oral acyclovir suggested an increase of unexplained nonlesional HSV episodes may occur during the early intervention period of acyclovir prophylaxis. Occasionally patients with this type of complaint will respond to acyclovir suppression, although the majority will not. For the indication of pain, alone, acyclovir should be tried only rarely, since it is not clear what its therapeutic role may be in the absence of regular genital mucocutaneous lesions.

HSV may also produce an ascending myelitis. This may be rapidly progressive, necrotising and fatal when it is usually associated with a purulent CSF. Less fulminating cases are associated with an aseptic meningitis. Cases occur in immunocompetent as well as immunocompromised hosts. AIDS patients may suffer an insidiously progressive myelopathy, dual infection of HSV with other viral pathogens such as CMV, and pathogenesis may differ with extensive infection occurring with minimal inflammation. Myelin basic protein has been suggested as a useful marker of disease activity. The pathogenesis of myelitis is also uncertain. The few documented pathological studies are consistent with immune-mediated demyelination and this has been supported by reports of response to and rebound on withdrawal of corticosteroids although cord infection has also been demonstrated. In view of the difficulty of isolation of HSV from the CSF of patients with neurological dysfunction it is quite possible that some cases of idiopathic myelitis may be due to HSV and that its incidence may be much more frequent than is currently appreciated.

Treatment of radiculomyelitis includes management of urinary retention by either intermittent or continuous urinary catheterisation, associated with symptomatic pain relief as this may contribute to retention. In cases of persistent dysfunction a suprapubic catheter is recommended. Cholinergic and alpha-sympatholytic agents have also been used. Trials of antiviral agents in radiculomyelitis have not been carried out; however, anecdotal reports of responses to ACV and proven efficacy of ACV in primary and recurrent genital herpes suggest specific antiviral treatment is indicated.

**Disseminated infection**

Disseminated HSV infection is usually seen in the setting of a host compromised by immunodeficiency such as bone marrow transplantation, malignancy (especially hematological in the setting of chemotherapy), malnutrition, alcoholism, pregnancy or the neonate. It is also seen in patients with integument defects such as burns and eczema, although cases in apparently normal hosts have been reported. Neonatal disease requires a review in itself and will not be more specifically addressed here.

Cell-mediated immune deficits seem most important. Even in the setting of profound immunosuppression, however, where HSV disease is typically chronic, erosive, and associated with prolonged viral shedding, only very rarely does HSV infection disseminate. When it does occur, dissemination may be either mucocutaneous or visceral or both. Mucocutaneous dissemination is an uncommon complication of primary genital
HSV infection where anecdotal reports of a satisfactory response to acyclovir have been reported. Most recently, cases of thymidine kinase-deficient, acyclovir-resistant HSV have been reported to cause disseminated mucocutaneous disease in AIDS patients. Foscarnet has generally proven an efficacious alternative therapy. The true incidence of dissemination may be higher than appreciated as autopsy studies have reported up to 6% incidence of HSV visceral dissemination. Although visceral dissemination may be a multisystem disease, isolated organ involvement, particularly of oesophagus, lung and liver, may also occur.

The oesophagus is by far the most common viscus involved, the incidence in autopsy studies ranging from 0.5% to 6%. It usually occurs as the sole organ involved. Antemortem diagnosis is rare and the majority of cases occur in the setting of malignancy. Oesophagitis may either result from direct extension from oropharyngeal disease or via reactivation through the vagus nerve. It presents with odynophagia, dysphagia, retrosternal and substernal pain, weight loss and fever although many cases are asymptomatic. On endoscopy one sees multiple oval ulcerations on an erythematous base with or without a white pseudomembrane. The distal oesophagus is most commonly involved.

HSV-1 is the usual aetiologic agent, although HSV-2 oesophagitis may occur. Although most cases are in immunocompromised hosts HSV oesophagitis does occur in normal hosts where it usually is part of a primary infection in males. The clinical course is self limited in normal hosts but progressive in compromised hosts if left untreated. Investigation by double contrast oesophagoscopy may display discrete, shallow, widely scattered ulcers. Endoscopy has the highest sensitivity and is the diagnostic procedure of choice, most commonly demonstrating discrete ulcers with a yellow rim of exudate or ulcer base, so-called "volcano ulcers". Differentiation from other causes of oesophagitis such as candida and peptic oesophagitis cannot be reliably made clinically and diagnosis relies on culture or cytological examination of biopsy specimens or aspirates. Candida and HSV may coexist as causes for oesophagitis. Other pathogens are common and it has been suggested that herpetic ulcers may provide a portal of entry for these which may contribute to pathology.

It has been reported that 0.3%–1.0% of all patients examined at autopsy have histological evidence of involvement with HSV of the lower respiratory tract, either as tracheobronchitis or pneumonia. In bone marrow recipients, HSV accounts for 6% of histologically-confirmed interstitial pneumonitis, usually the result of endogenous reactivation, with either local extension of oral herpetic infection down the tracheobronchial tree into lung parenchyma resulting in focal necrotising pneumonia or haematogenous spread from oral or genital mucocutaneous lesions to result in bilateral interstitial pneumonitis. It is interesting that latent HSV has also been found in human vaginal ganglia. Thus, reactivation with neurogenic spread may also provide a possible mechanism of both respiratory and oesophageal infection. Tracheal trauma due to intubation (which may also predispose to aspiration), burns, or areas of squamous metaplasia from smoking can also predispose to direct spread. Clinical and radiological findings are nonspecific and include fever, cough, respiratory insufficiency and focal or diffuse pulmonary infiltrates. Mucocutaneous HSV lesions often antedate pneumonia but may be absent. Other serious concomitant bacterial and fungal pathogens are common. Mortality is high but, untreated, the illness is not invariably fatal, particularly in normal hosts, and the incidence of mild self-resolving disease is unknown. HSV has been reported to occur in 30% of intubated patients with acute respiratory distress syndrome (ARDS). Such patients may have more respiratory insufficiency than those without HSV but the relationship of HSV to the pathogenesis of ARDS is uncertain.

Diagnosis is dependent on histological evidence of pneumonitis together with isolation of virus from lung and investigation should include bronchoscopy which may visualise ulcerations or membranes of the respiratory tract and which allows collection of cytological specimens by washings and brushings and histological specimens by biopsy. Viral culture of sputum or throat washings, alone, are often falsely positive due asymptomatic salivary shedding in ill patients. Direct immunofluorescence or immunoperoxidase staining of infected tissue may also be helpful in establishing the presence of infection rapidly.

HSV is an uncommon cause of viral hepatitis. In solid organ transplant recipients it occurs at a frequency of 0.3% and is an early manifestation, occurring a median of 18 days (range 5–46) post transplant, sooner than cytomegalovirus (CMV) infection which occurs 30–40 days post transplantation. It can occur as either primary or reactivation disease. The majority of cases of HSV hepatitis occur in the setting of disseminated infection, however, isolated hepatitis may also occur. Concomitant dissemination is reflected in a reported mortality rate of 60–86%, even in normal hosts. Pathology may be focal, associated with a good prognosis and response to antiviral chemotherapy or diffuse, associated with disseminated intravascular coagulation (DIC) and a poor prognosis regardless of antiviral intervention. Hepatitis is the most common manifestation of dissemination in pregnancy where it is most often associated with primary infection in the third trimester and results in a 60% fetal wastage rate.

Clinical and laboratory presentations include fever, abdominal pain and tenderness, elevations of bilirubin and transaminases, either leukopenia or leukocytosis, increased band forms, atypical lymphocytes, DIC, and abnormal chest radiograms. Only 25–94% of patients have associated mucocutaneous disease and the absence of such lesions should
Herpes latency, meningitis, radiculomyelopathy and disseminated infection

not deter the clinician from entertaining the diagnosis. Over half of cases are diagnosed in extremis or post mortem. Associated extrahepatic visceral involvement is common and is rarely diagnosed antemortem. Notably, the majority of cases of HSV hepatitis are anicteric. Accordingly, a high degree of suspicion in appropriate patients is required. In view of the fulminant nature of the disease, suspected cases should be treated with empirical antivirals immediately. Fourteen percent of healthy adults with acute primary or recurrent genital herpes may also have minor elevations of liver enzymes, suggesting minor cases of hepatitis may be more frequent than currently appreciated, although this is highly speculative. Diagnosis rests on detection of virus by culture or histopathology in liver biopsy specimens.

Other rarely reported manifestations of disseminated infection include monocarticular arthritis, idiopathic thrombocytopenia, glomerulonephritis, colitis, localised lymphadenitis and haemorrhagic cystitis possibly precipitated by catheterisation, adrenal necrosis, pancreatitis, encephalitis, myocarditis and splenic infection.

Acyclovir is effective therapy and is superior to vidarabine, as evidenced by treatment trials against HSV encephalitis in man, as well as studies of disseminated HSV infection in animal models. Anecdotal reports of acyclovir efficacy, and the proven efficacy of this treatment for genital herpes, as well as the severity of infection, mandate therapy with acyclovir. Another systemic antiviral, penciclovir, or its oral formulation, famciclovir, has not been specifically used in this setting, but may prove to be interesting alternatives for the future. Furthermore, valaciclovir, a much more bioavailable prodrug of acyclovir is currently undergoing extensive clinical study. Prophylaxis with oral acyclovir in immunocompromised hosts has also been found to be efficacious and has been reported to eliminate dissemination in one centre. Of more recent concern is a report of ACV-resistant herpes oesophagitis due to a polymerase mutant, as well as proof of establishment of latent resistant HSV in a nonimmunocompromised host. With an ever growing immunocompromised population, HSV resistance is likely to occur with increasing frequency.

Conclusions

This review has tried to shed some light on and bring up to date the gradually unravelling enigma of how HSV establishes, maintains itself in and reactivates itself from latency, a phenomenon fundamental to the pathogenesis of herpes virus infections. In addition, it has sought to elucidate the presentations, pathogenesis and treatment of several lesser known neurological manifestations as well as the potentially disastrous complication of disseminated infection, which continues to increase owing to an ever increasing population of immunocompromised individuals, in turn caused by more widespread organ transplantation as well as the growing HIV pandemic.

29 Coen DM, Rouzet-Ventchak M, Jacobson J, et al. Thyroiditis kinase-negative herpes simplex virus variants establish latency in mouse trigeminal ganglia but do not


Herpes latency, meningitis, radiculomyelopathy and disseminated infection


100 Graham BS, Snell JD. Herpes simplex virus infection of the adult respiratory tract. Medicine (Baltimore) 1983; 62:384-93.


